Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Onyx Pharmaceuticals, Inc. v. Bayer Corp.

November 16, 2010

ONYX PHARMACEUTICALS, INC., PLAINTIFF,
v.
BAYER CORPORATION, ET AL., DEFENDANTS.



The opinion of the court was delivered by: The Honorable Marilyn H. Patel United States District Court Judge

STIPULATION AND [PROPOSED] ORDER REVISING TRIAL DATE AND PRETRIAL SCHEDULE AS AMENDED BY COURT

IT IS HEREBY STIPULATED by and between plaintiff Onyx Pharmaceuticals, Inc. ("Onyx") and defendants Bayer Corporation, Bayer AG, Bayer HealthCare LLC and Bayer Schering Pharma AG (collectively, "Bayer") as follows:

1. WHEREAS, on August 21, 2009, the parties submitted the initial joint case management statement proposing trial in May 2011, and on August 31, 2009, as a result of the initial case management conference, this Court entered an Order setting this matter for trial on May 17, 2011;

2. WHEREAS, on August 2, 2010, the Court entered a supplemental case management Order that shifted some dates but maintained the May 17, 2010 trial date;

3. WHEREAS, the parties have been extremely busy producing millions of pages of documents and completing 20 depositions all over the world. But given the remaining discovery, the parties respectfully request an approximate four-week extension of remaining due dates as set forth below. The parties also proposed additional language to provide clarity regarding what needs to be accomplished on each date;

4. WHEREAS, Onyx believes the trial date need not be continued, but is willing to compromise and agree to this approximate four-week extension. Onyx only agrees to this new schedule, however, if the Court can accommodate a trial beginning on June 13, 2011. Otherwise, Onyx believes the Court should adopt the stipulated deadlines below for fact discovery and expert discovery (events 1, 2, 3 and 6) and should maintain all other deadlines according to the current schedule; shifted at least 90 days but is willing to compromise and agree to this approximate four-week extension. Bayer remains hopeful that, if both parties use their best efforts, the remaining discovery can be accomplished and the parties can heed these proposed new dates. But given the tightness of the proposed schedule, should circumstances necessitate, Bayer reserves the right to request a further extension of the schedule if necessary and upon a showing of good cause.

Bayer believes that Onyx's alternative proposal (should the Court not be able to accommodate a trial beginning on June 13, 2011) to shift some of the deadlines but not others is unworkable and creates conflicts and prejudice; and

6. WHEREAS, the remaining discovery outstanding includes: Ten fact depositions, two of which require international travel; Twenty hours of deposition for individuals listed on the parties' witness lists who have not yet been deposed;

Bayer's responses to Onyx's twenty new requests for production, which were timely served on October 19, 2010;

Bayer's responses to Onyx's seventeen new interrogatories (Bayer believes there are more than seventeen given subparts), which were timely served on October 19, 2010;

Bayer's responses to Onyx's eighteen new requests for admission, which were timely served on October 19, 2010;

Production of documents by Onyx in response to Bayer's ten new requests for production, which were timely served on October 12, 2010; and Production of documents by both parties from certain new custodians,

THEREFORE, the parties stipulate and jointly move the Court to enter a revised case management Order reflecting ...


Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.